Cinnamaldehyde impairs high glucose-induced hypertrophy in renal interstitial fibroblasts

Toxicology and Applied Pharmacology

Volumn 244, Issue 2, 2010, Pages 174-180

  Chao, Louis Kuoping ^a   Chang, Wen Teng ^b   Shih, Yuan Wei ^b   Huang, Jau Shyang ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

Apoptosis; Cinnamaldehyde; High glucose; Hypertrophy; Renal interstitial fibroblasts

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA SMOOTH MUSCLE ACTIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CINNAMALDEHYDE; COLLAGEN TYPE 4; CYTOCHROME C; FIBRONECTIN; GLUCOSE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SB 2035580; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INTERSTITIUM; MITOGENESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION;

ACROLEIN; DIABETIC NEPHROPATHIES; FIBROBLASTS; GLUCOSE; HUMANS; HYPERTROPHY; KIDNEY; MAP KINASE SIGNALING SYSTEM; NEPHRITIS, INTERSTITIAL;

CINNAMOMUM OSMOPHLOEUM;

EID: 77950064310     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.030     Document Type: Article

References (34)

1. Bohlender J.M., Franke S., Stein G., Wolf G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal. Physiol. 2005, 289:645-659.
2. Cabello C.M., Bair W.B., Lamore S.D., Ley S., Bause A.S., Azimian S., Wondrak G.T. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic. Biol. Med. 2009, 46:220-231.
3. Chang S.T., Chen P.F., Chang S.C. Antibacterial activity of leaf essential oils and their constituents from Cinnamomum osmophloeum. J. Ethnopharmacol. 2001, 77:123-127.
4. Chao L.K., Hua K.F., Hsu H.Y., Cheng S.S., Liu J.Y., Chang S.T. Study on the antiinflammatory activity of essential oil from leaves of Cinnamomum osmophloeum. J. Agric. Food Chem. 2005, 53:7274-7278.
5. Chao L.K., Hua K.F., Hsu H.Y., Cheng S.S., Lin I.F., Chen C.J., Chen S.T., Chang S.T. Cinnamaldehyde inhibits pro-inflammatory cytokines secretion from monocytes/macrophages through suppression of intracellular signaling. Food Chem. Toxicol. 2008, 46:220-231.
6. Cheng S.S., Liu J.Y., Tsai K.H., Chen W.J., Chang S.T. Chemical composition and mosquito larvicidal activity of essential oils from leaves of different Cinnamomum osmophloeum provenances. J. Agric. Food Chem. 2004, 52:4395-4400.
7. Cheng S.S., Liu J.Y., Hsui Y.R., Chang S.T. Chemical polymorphism and antifungal activity of essential oils from leaves of different provenances of indigenous cinnamon (Cinnamomum osmophloeum). Bioresour. Technol. 2006, 97:306-312.
8. Duessel S., Heuertz R.M., Ezekiel U.R. Growth inhibition of human colon cancer cells by plant compounds. Clin. Lab. Sci. 2008, 21:151-157.
9. Forbes J.M., Fukami K., Cooper M.E. Diabetic nephropathy: where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 2007, 115:69-84.
10. Fukami K., Yamagishi S., Ueda S., Okuda S. Novel therapeutic targets for diabetic nephropathy. Endocr. Metab. Immune Disord. Drug Targets 2007, 7:83-92.
11. Ha H.B., Lee H. Reactive oxygen species and matrix remodeling in diabetic kidney. J. Am. Soc. Nephrol. 2003, 14:S246-S249.
12. Ha H., Yu M.R., Choi Y.J., Kitamura M., Lee H.B. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 2002, 13:894-902.
13. Hewitson T.D. Renal tubulointerstitial fibrosis: common but never simple. Am. J. Physiol. Renal. Physiol. 2009, 296:F1239-F1244.
14. Ibraghimov B.O. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 2007, 6:776-779.
15. Iwano M., Neilson E.G. Mechanisms of tubulointerstitial fibrosis. Curr. Opin. Nephrol. Hypertens. 2004, 13:279-284.
16. Ka H., Park H.J., Jung H.J., Choi J.W., Cho K.S., Ha J., Lee K.T. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett. 2003, 196:143-152.
17. Koh W.S., Yoon S.Y., Kwon B.M., Jeong T.C., Nam K.S., Han M.Y. Cinnamaldehyde inhibits lymphocyte proliferation and modulates T-cell differentiation. Int. J. Immunopharmacol. 1998, 20:643-660.
18. Lee H.B., Yu M.R., Yang Y., Jiang Z., Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:S241-S245.
19. Lee E.A., Seo J.Y., Jiang Z., Yu M.R., Kwon M.K., Ha H., Lee H.B. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005, 67:1762-1771.
20. Lee C.W., Lee S.H., Lee J.W., Ban J.O., Lee S.Y., Yoo H.S., Jung J.K., Moon D.C., Oh K.W., Hong J.T. 2-hydroxycinnamaldehyde inhibits SW620 colon cancer cell growth through AP-1 inactivation. J. Pharmacol. Sci. 2007, 104:19-28.
21. Leehey D.J., Singh A.K., Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int. Suppl. 2000, 77:S93-S98.
22. Li M.X., Liu B.C. Epithelial to mesenchymal transition in the progression of tubulointerstitial fibrosis. Chin. Med. J. (Engl). 2007, 120:1925-1930.
23. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern. Med. 2004, 43:9-17.
24. Niedowicz D.M., Daleke D.L. The role of oxidative stress in diabetic complications. Cell. Biochem. Biophys. 2005, 43:289-330.
25. Nistala R., Whaley-Connell A., Sowers J.R. Redox control of renal function and hypertension. Antioxid. Redox. Signal. 2008, 10:2047-2089.
26. Rastaldi M.P. Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J. Nephrol. 2006, 19:407-412.
27. Schutta M.H. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J. Cardiometab. Syndr. 2007, 2:124-130.
28. Smith C.K., Moore C.A., Elahi E.N., Smart A.T., Hotchkiss S.A. Human skin absorption and metabolism of the contact allergens, cinnamic aldehyde, and cinnamic alcohol. Toxicol. Appl. Pharmacol. 2000, 168:189-199.
29. Subash B.P., Prabuseenivasan S., Ignacimuthu S. Cinnamaldehyde-a potential antidiabetic agent. Phytomedicine 2007, 14:15-22.
30. Tung Y.T., Chua M.T., Wang S.Y., Chang S.T. Anti-inflammation activities of essential oil and its constituents from indigenous cinnamon (Cinnamomum osmophloeum) twigs. Bioresour. Technol. 2008, 99:3908-3913.
31. Wang W., Koka V., Lan H.Y. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005, 10:48-56.
32. Wolf G., Ziyadeh F.N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron. Physiol. 2007, 106:26-31.
33. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug. Targets 2007, 8:952-959.
34. Zhang W., Xu Y.C., Guo F.J., Meng Y., Li M.L. Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chin. Med. J. (Engl). 2008, 121:2124-2128.